1417 related articles for article (PubMed ID: 33958323)
1. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.
Bonelli MM; Mrak D; Perkmann T; Haslacher H; Aletaha D
Ann Rheum Dis; 2021 Oct; 80(10):1355-1356. PubMed ID: 33958323
[No Abstract] [Full Text] [Related]
2. Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies.
Amodio D; Ruggiero A; Sgrulletti M; Pighi C; Cotugno N; Medri C; Morrocchi E; Colagrossi L; Russo C; Zaffina S; Di Matteo G; Cifaldi C; Di Cesare S; Rivalta B; Pacillo L; Santilli V; Giancotta C; Manno EC; Ciofi Degli Atti M; Raponi M; Rossi P; Finocchi A; Cancrini C; Perno CF; Moschese V; Palma P
Front Immunol; 2021; 12():727850. PubMed ID: 34671350
[TBL] [Abstract][Full Text] [Related]
3. Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series.
Connolly CM; Chiang TP; Boyarsky BJ; Ruddy JA; Teles M; Alejo JL; Massie A; Werbel WA; Shah AA; Christopher-Stine L; Garonzik-Wang J; Segev DL; Paik JJ
Ann Rheum Dis; 2022 Feb; 81(2):293-295. PubMed ID: 34556484
[No Abstract] [Full Text] [Related]
4. Effect of Immunosuppression on the Immune Response to SARS-CoV-2 Infection and Vaccination.
Leacy EJ; Teh JW; O'Rourke AM; Brady G; Gargan S; Conlon N; Scott J; Dunne J; Phelan T; Griffin MD; Power J; Mooney A; Naughton A; Kiersey R; Gardiner M; O'Brien C; Mullan R; Flood R; Clarkson M; Townsend L; O'Shaughnessy M; Dyer AH; Moran B; Fletcher JM; Zgaga L; Little MA;
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791279
[TBL] [Abstract][Full Text] [Related]
5. Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases.
Sieiro Santos C; Calleja Antolin S; Moriano Morales C; Garcia Herrero J; Diez Alvarez E; Ramos Ortega F; Ruiz de Morales JG
RMD Open; 2022 Jan; 8(1):. PubMed ID: 34987093
[TBL] [Abstract][Full Text] [Related]
6. Humoral and cellular response of two different vaccines against SARS-CoV-2 in a group of healthcare workers: Comment.
Daungsupawong H; Wiwanitkit V
J Immunol Methods; 2024 Jun; 529():113671. PubMed ID: 38593868
[No Abstract] [Full Text] [Related]
7. Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination.
Barouch DH; Stephenson KE; Sadoff J; Yu J; Chang A; Gebre M; McMahan K; Liu J; Chandrashekar A; Patel S; Le Gars M; de Groot AM; Heerwegh D; Struyf F; Douoguih M; van Hoof J; Schuitemaker H
N Engl J Med; 2021 Sep; 385(10):951-953. PubMed ID: 34260834
[No Abstract] [Full Text] [Related]
8. A vaccination update for rheumatologists-SARS-CoV-2, influenza and herpes zoster.
Wong PKK; Lahiri M; Lye DC; Johnson D; Charles PGP
Int J Rheum Dis; 2021 Aug; 24(8):979-983. PubMed ID: 34350721
[No Abstract] [Full Text] [Related]
9. Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series.
Connolly CM; Teles M; Frey S; Boyarsky BJ; Alejo JL; Werbel WA; Albayda J; Christopher-Stine L; Garonzik-Wang J; Segev DL; Paik JJ
Ann Rheum Dis; 2022 Feb; 81(2):291-293. PubMed ID: 34493492
[No Abstract] [Full Text] [Related]
10. Impact of Prior COVID-19 Immunization and/or Prior Infection on Immune Responses and Clinical Outcomes.
Livieratos A; Gogos C; Akinosoglou K
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793566
[TBL] [Abstract][Full Text] [Related]
11. Antibody, not Cellular, Immune Responses to SARS-CoV-2 Vaccination Outperform Infection in Inflammatory Bowel Disease Patients.
González Cueto E; Edmans M; Wellens J; Cadwell K; Thompson C; Satsangi J; Wong SY;
Inflamm Bowel Dis; 2024 May; 30(5):859-862. PubMed ID: 37935466
[No Abstract] [Full Text] [Related]
12. Immunogenicity of COVID-19 vaccines in patients with cirrhosis: A meta-analysis.
Ouyang L; Lei G; Gong Y
Hum Vaccin Immunother; 2024 Dec; 20(1):2326316. PubMed ID: 38466197
[TBL] [Abstract][Full Text] [Related]
13. Interim effectiveness of the updated 2023-2024 COVID-19 vaccines in adults with immunocompromizing conditions.
Pereira MR
Am J Transplant; 2024 Jun; 24(6):890-891. PubMed ID: 38677653
[No Abstract] [Full Text] [Related]
14. Divergent Immune Responses to SARS-CoV-2 Vaccines in Immunocompromised Patients.
Jordan SC; Shin BH; Gadsden TM; Chu M; Petrosyan A; Vo A; Ammerman N; Sethi S; Najjar R; Huang E; Peng A; Toyoda M; Kumar S; Zhang R
Transplantation; 2022 Jan; 106(1):e90-e91. PubMed ID: 34582140
[TBL] [Abstract][Full Text] [Related]
15. Safety of SARS-CoV-2 mRNA vaccines and effects of immunosuppressive drugs on adverse reactions in patients with rheumatic diseases.
Kawazoe M; Nishio J; Hirose W; Furukawa K; Nanki T
Eur J Intern Med; 2023 Sep; 115():137-139. PubMed ID: 37339924
[No Abstract] [Full Text] [Related]
16. Correspondence on "Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry" by Machado
Bourguiba R; Delplanque M; Savey L; Hentgen V; Grateau G; Georgin-Lavialle S;
Ann Rheum Dis; 2023 Dec; 82(12):e228. PubMed ID: 35817471
[No Abstract] [Full Text] [Related]
17. COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial.
Agrati C; Di Cosimo S; Fenoglio D; Apolone G; Ciceri F; Ciliberto G; Baldanti F; Costantini M; Giannarelli D; Ippolito G; Locatelli F; Mantovani A; Morrone A; Tagliavini F; Uccelli A; Zinzani PL; Silvestris N; Rescigno M
Front Immunol; 2021; 12():704110. PubMed ID: 34447374
[TBL] [Abstract][Full Text] [Related]
18. Response to: 'Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease'' by C
D'Silva KM; Serling-Boyd N; Hsu TY; Sparks JA; Wallace ZS
Ann Rheum Dis; 2023 Jun; 82(6):e131. PubMed ID: 33692020
[No Abstract] [Full Text] [Related]
19. Boosting SARS-CoV-2 immunity in immunocompromised individuals.
Müller TR; Buggert M
Genes Immun; 2024 Apr; 25(2):168-169. PubMed ID: 38114640
[No Abstract] [Full Text] [Related]
20. SARS-CoV-2-specific immunity in immunosuppressed COVID-19 convalescents with autoimmune hepatitis.
Kirchner T; Jaeckel E; Falk CS; Eiz-Vesper B; Taubert R
J Hepatol; 2021 Dec; 75(6):1506-1509. PubMed ID: 34284030
[No Abstract] [Full Text] [Related]
[Next] [New Search]
